Shanyn Wilhite
Family · Hoover, ALNPI 1639584097
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 930 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 930 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AbbVie$2K
- Lilly USA, LLC$1K
- Dexcom, Inc.$1K
- Bayer$930
- Pfizer$703
- plus $6K from 54 others
What the payments were for
- Food & beverage$14,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,156 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $42,790 |
| JardianceEmpagliflozin | 48 | $42,066 |
| MounjaroTirzepatide | 32 | $33,290 |
| LinzessLinaclotide | 22 | $17,768 |
| JanuviaSitagliptin Phosphate | 16 | $11,872 |
| XareltoRivaroxaban | 11 | $8,329 |
| Atorvastatin Calcium | 143 | $2,865 |
| Levothyroxine Sodium | 111 | $1,395 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $1,010 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 25 | $929 |
| Glipizide ErGlipizide | 25 | $801 |
| Omeprazole | 45 | $741 |
| Losartan Potassium | 57 | $739 |
| Ezetimibe | 27 | $719 |
| Fenofibrate | 13 | $718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,779 | $42,79035 claims |
| Boehringer IngelheimJardiance | $205 | $42,06648 claims |
| Lilly USA, LLCMounjaro | $1,408 | $33,29032 claims |
| AbbVieLinzess | $1,588 | $17,76822 claims |
| MerckJanuvia | $103 | $11,87216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Hoover
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
- Julia BettsHuntsville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.